Literature DB >> 22383181

Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension.

Michele Correale, Deodata Montrone, Matteo Di Biase, Natale Daniele Brunetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22383181     DOI： 10.1007/s00392-012-0437-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  9 in total

1.  Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.

Authors:  Sebastian Nuding; Henning Ebelt; Robert S Hoke; Annette Krummenerl; Andreas Wienke; Ursula Müller-Werdan; Karl Werdan
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

2.  Predictors of mortality and morbidity in patients with chronic heart failure.

Authors:  Stuart J Pocock; Duolao Wang; Marc A Pfeffer; Salim Yusuf; John J V McMurray; Karl B Swedberg; Jan Ostergren; Eric L Michelson; Karen S Pieper; Christopher B Granger
Journal:  Eur Heart J       Date:  2005-10-11       Impact factor: 29.983

Review 3.  Pharmacotherapeutic management of pulmonary arterial hypertension.

Authors:  Joe R Anderson; James J Nawarskas
Journal:  Cardiol Rev       Date:  2010 May-Jun       Impact factor: 2.644

4.  Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic.

Authors:  Pavel Jansa; Radim Becvar; David Ambroz; Tomas Palecek; Michal Tomcik; Simona Skacelova; Michael Aschermann; Ales Linhart
Journal:  Clin Rheumatol       Date:  2011-11-22       Impact factor: 2.980

Review 5.  Pulmonary arterial hypertension: an update on diagnosis and treatment.

Authors:  Richard Stringham; Nipa R Shah
Journal:  Am Fam Physician       Date:  2010-08-15       Impact factor: 3.292

6.  Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.

Authors:  Karl Werdan; Henning Ebelt; Sebastian Nuding; Florian Höpfner; Guido Hack; Ursula Müller-Werdan
Journal:  Clin Res Cardiol       Date:  2012-01-10       Impact factor: 5.460

7.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

Review 8.  Resting heart rate in cardiovascular disease.

Authors:  Kim Fox; Jeffrey S Borer; A John Camm; Nicolas Danchin; Roberto Ferrari; Jose L Lopez Sendon; Philippe Gabriel Steg; Jean-Claude Tardif; Luigi Tavazzi; Michal Tendera
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

Review 9.  Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.

Authors:  Genevieve Flannery; Rosie Gehrig-Mills; Baki Billah; Henry Krum
Journal:  Am J Cardiol       Date:  2008-02-21       Impact factor: 2.778
  9 in total
  2 in total

Review 1.  Update on systemic sclerosis.

Authors:  Courtney J McCray; Maureen D Mayes
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

2.  Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?

Authors:  Michele Correale; Deodata Montrone; Riccardo Ieva; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Clin Res Cardiol       Date:  2013-02-07       Impact factor: 5.460
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.